Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Prelude Therapeutics Inc

PRLD ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$5.55

▲ +3.54%

Market Cap $442.91M · Vol 165.01K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$442.91M

Small Cap

Div Yield

N/A

EPS Growth

+75.45%

YoY

RSI (14)

71.50

Momentum

Beta

0.98

vs Market

52W High

$5.91

6.09% below

52W Low

$0.82

575.10% above

Volume

165.01K

Avg 128.43K

P/B

2.66

Price-to-book

ROE

N/A

Return on equity

Free Float

68.09%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Prelude Therapeutics Inc (PRLD) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PRLD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+13.27%

+26.42%

+24.16%

+148.88%

YTD

+91.38%

+487.30%

+47.21%

-82.75%

Financials & Valuation

TTM · Annual

Total Revenue	$12.14M
Net Income	$-99,498,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-861.33%
Net Profit Margin	-819.59%
ROE	N/A
ROA · ROIC	-62.81% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	18.38
P/B	2.66
P/FCF	N/A
EPS Growth	+75.45%
Outstanding Shares	79.80M

Technical Indicators

50-Day SMA	$4.52
200-Day SMA	$3.30
RSI (14)	71.50
Beta	0.98
52-Week High	$5.91
52-Week Low	$0.82

Volume Today	165.01K
Avg Daily Volume (30D)	128.43K
Relative Volume	1.28x
Volatility (10D)	76.30
Volatility (30D)	85.80
Free Float	68.09%

Analyst Consensus

BUY

Current Price $5.55

Mean Target $8.00

52W Low$0.82 52W High$5.91

Current

Target

$0.82 $5.91

Current Analyst target

+44.14% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00K7JY2R5

ISINUS74065P1012

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Prelude Therapeutics Incorporated is a precision oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, it has developed a diverse pipeline consisting of multiple distinct programs, including kinases, targeted protein degraders, and degrader antibody conjugates. PRT12396 its lead, mutant-selective JAK2V617F inhibitor, is an open-label and multi-center study in patients with high-risk polycythemia vera and intermediate and high-risk myelofibrosis. JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms. The Company has discovered and is developing a series of selective and orally bioavailable KAT6A selective degraders. KAT6A is engaged in treating advanced breast cancer & other solid tumors.